Previous 10 | Next 10 |
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief E...
Summary Seth Klarman’s 13F portfolio value increased from $5.79B to $6.13B this quarter. Baupost Group increased Alphabet and Meta Platforms while dropping Dropbox and Encompass Health. The portfolio continues to be heavily concentrated with the top three positions accounting...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief E...
The following slide deck was published by Atara Biotherapeutics, Inc. in conjunction with their 2023 Q4 earnings call. For further details see: Atara Biotherapeutics, Inc. 2023 Q4 - Results - Earnings Call Presentation
Summary Atara is a cell therapy focused biotech with a unique approach based on a novel allogeneic Epstein-Barr virus (EBV) T-cell platform. The company secured the first ever approval of an allogeneic cell therapy in December last year - albeit in a niche indication. In 2023 there ...
Atara Biotherapeutics press release ( NASDAQ: ATRA ): Q4 GAAP EPS of -$0.72 misses by $0.30 . Revenue of $0.22M (-97.1% Y/Y) misses by $39.45M . For further details see: Atara Biotherapeutics GAAP EPS of -$0.72 misses by $0.30, revenue of $0.22M misses by $39.45M
Ebvallo™ EU Launch Activities Led by Pierre Fabre to Commence in Q1 2023 Discussions with FDA Progressing on Potential U.S. BLA for Tab-cel ® ATA188 Phase 2 EMBOLD Study Primary Data Readout On-Track for October 2023 Cash Runway Extended into Q2 2024 ...
Atara Biotherapeutics ( NASDAQ: ATRA ) transfered the European Commission (EC) marketing authorization (MA) of Ebvallo to Pierre Fabre. The two companies' drug Ebvallo (tabelecleucel) was approved in December 2022 by EC to treat patients two years of age and older ...
Pierre Fabre to Lead Launch and Commercialization Activities for EBVALLO ™ In Europe Following Transfer of European Commission Marketing Authorization from Atara Biotherapeutics EBVALLO ™ is the Only Approved Therapy for the Treatment of Relapsed or Refra...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release fourth quarter an...
News, Short Squeeze, Breakout and More Instantly...
Atara Biotherapeutics Inc. Company Name:
ATRA Stock Symbol:
NASDAQ Market:
Atara Biotherapeutics Inc. Website:
Prescription Drug User Fee Act (PDUFA) Target Action Date of January 15, 2025 If Approved, Tab-cel Would Be First Approved Therapy in U.S. for EBV+ PTLD BLA Acceptance Triggers $20 Million Milestone Payment from Pierre Fabre Laboratories, with Additional $60 Million Milestone if A...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief E...
2024-06-27 22:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...